文献速递生殖医学

州保险强制令对供卵辅助生殖技术利用及结局种族/民族差异的影响

Effect of state insurance mandates on racial/ethnic disparities in the utilization and outcomes of donor oocyte-assisted reproductive technologies.
PubMed 文献 · Fertil Steril · 2023-03-05

该回顾性队列研究分析了2014-2016年美国44,033个供卵辅助生殖技术周期(28,157名受卵者),发现黑种人受卵者累计活产概率低于白种人(RR 0.82,95%CI 0.77-0.87),西班牙裔(RR 0.93,95%CI 0.89-0.99)和亚裔(RR 0.96,95%CI 0.93-0.99)亦较低,且这些差异未受州强制令影响。作者结论认为现行州强制令不足以减少种族/民族差异。

要点

  • 黑种人受卵者累计活产概率低于白种人(RR 0.82,95%CI 0.77-0.87)。
  • 西班牙裔(RR 0.93,95%CI 0.89-0.99)和亚裔(RR 0.96,95%CI 0.93-0.99)受卵者累计活产概率亦低于白种人。
  • 州强制令未改变上述种族/民族差异。

核心结论

  • 现行形式的州供卵辅助生殖技术强制令不足以减少种族/民族差异。

研究设计与样本

  • 回顾性队列研究,分析2014-2016年向美国辅助生殖技术协会临床结局报告系统报告的供卵辅助生殖技术周期,共44,033个周期,涉及28,157名受卵者。

主要发现

  • 在25-54岁且有种族数据的受卵者中,非西班牙裔白种人占65.8%(11,264/17,128),黑种人占8.3%。
  • 白种人受卵者在无强制令州和有强制令州的累计活产概率分别为64.6%(6,820/10,565)和69.5%(550/791)。
  • 黑种人受卵者在无强制令州和有强制令州的累计活产概率分别为48.7%(655/1,346)和48.4%(45/93)。
  • 多变量泊松回归显示,黑种人受卵者累计活产概率低于白种人(RR 0.82;95%CI 0.77-0.87),西班牙裔(RR 0.93;95%CI 0.89-0.99)和亚裔(RR 0.96;95%CI 0.93-0.99)亦较低。
  • 这些差异未受州供卵辅助生殖技术强制令影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize racial/ethnic disparities in donor oocyte-assisted reproductive technology (ART) nationwide and examine the impact of state insurance mandates on disparities in utilization and outcomes. DESIGN: Retrospective cohort study. SETTING: Donor oocyte ART cycles in the United States (US). PATIENT(S): Women who underwent donor oocyte ART in 2014-2016, as reported to the Society for Assisted Reproductive Technology Clinic Outcome Reporting System. INTERVENTION(S): Race/ethnicity of oocyte recipients. MAIN OUTCOME MEASURE(S): Live birth through 1 or more donor oocyte ART cycles in 2014-2016 per recipient. RESULT(S): We analyzed 44,033 donor ART cycles performed for 28,157 oocyte recipients, 99.2% (27,919/28,157) of whom were aged 25-54 years. Race/ethnicity data were reported for 61.4% (17,281/28,157) of the recipients. Among recipients aged 25-54 years with race data, 65.8% (11,264/17,128) identified as non-Hispanic White, whereas 58.9% were White among women aged 25-54 in the 2016 US census. In contrast, Black recipients comprised 8.3% of those aged 25-54 years with race data, compared with 13.7% nationwide. Among White recipients, 7.0% (791/11,356) lived in states with donor ART mandates (Massachusetts/New Jersey), compared with 6.5% (93/1,439) of Black recipients, 8.1% (108/1,335) of Hispanic recipients, and 5.8% (184/3,151) of Asian recipients. Black recipients had a higher median age and body mass index and were more likely to have uterine factor infertility. White recipients had the highest cumulative probability of live birth in the nonmandate (64.6%, 6,820/10,565) and mandate (69.5%, 550/791) states, followed by Asian recipients (nonmandate, 63.4% [1,881/2,967]; mandate, 65.2% [120/184]), Hispanic recipients (nonmandate, 60.5% [742/1,227]; mandate, 68.5% [74/108]), and Black recipients (nonmandate, 48.7% [655/1,346]; mandate, 48.4% [45/93]). The multivariable Poisson regression adjusting for donor's age and recipient's age, body mass index, nulliparity, history of recurrent pregnancy loss, diminished ovarian reserve, tubal factor and uterine factor infertility, prior ART treatment, use of preimplantation genetic testing, cumulative number of embryos transferred, use of blastocysts, and frozen-thawed transfers, demonstrated that Black recipients had a lower cumulative probability of a live birth than White recipients (relative risk [RR], 0.82; 95% confidence interval [CI], 0.77-0.87), as were Hispanic recipients (RR, 0.93; 95% CI, 0.89-0.99) and Asian recipients (RR, 0.96; 95% CI, 0.93-0.99). These disparities were not modified by state mandate for donor ART. CONCLUSION(S): State mandates for donor oocyte ART in their current forms are insufficient in decreasing racial/ethnic disparities.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Liao C, Kotlyar AM, Seifer DB, et al. Effect of state insurance mandates on racial/ethnic disparities in the utilization and outcomes of donor oocyte-assisted reproductive technologies. Fertil Steril. 2023. PMID: 36871857. doi:10.1016/j.fertnstert.2023.02.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。